Preoperative Role of Systemic Immune Indices in the Differential Diagnosis between Chromophobe Renal Cell Carcinoma and Oncocytoma
Urologia Internationalis · 2025
DOI: 10.1159/000549555 ↗Kurz gefasst
Fachartikel in der Zeitschrift Urologia Internationalis, 2025. Verfasst von Semih Aktaş und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Health Sciences University, Hamidiye Faculty of Medicine, Istanbul Health Practice and Research Center, Istanbul, Turkey. Hauptthemen laut MEDLINE: Adenoma, Oxyphilic, Carcinoma, Renal Cell, Kidney Neoplasms. Die Arbeit nennt 13 Literaturangaben.
Abstract (Originalsprache)
Introduction
The aim of this study was to explore the role of systemic immune indices (systemic immune-inflammation index [SII] and systemic inflammatory response index [SIRI]) in the differential diagnosis between chromophobe renal cell carcinoma (chRCC) and oncocytoma.
Methods
The medical records of 162 patients diagnosed with chRCC and 90 patients with oncocytoma, who underwent surgery for renal masses between January 2013 and December 2022, were reviewed. Inflammatory indices, including neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), monocyte-to-lymphocyte ratio (MLR), SII, and SIRI, were calculated for both groups. The results were compared to assess the effects of these markers on renal cell carcinoma (RCC) subtypes.
Results
Median age was significantly higher in the oncocytoma group (65 vs. 61 years, p = 0.01). Tumor size was larger in the chRCC group (p < 0.001). NLR, MLR, PLR, SII, and SIRI values were significantly higher in chRCC (all p < 0.001). ROC analysis showed area under the curve (AUC) values of 0.688 (NLR), 0.673 (MLR), 0.750 (PLR), 0.720 (SII), and 0.679 (SIRI). The optimal SII cut-off was 460 (AUC: 0.692), and for SIRI, 0.7 (AUC: 0.647), offering the best discriminative performance between chRCC and oncocytoma.
Conclusion
Inflammatory indices, particularly PLR, SII, and SIRI, are accessible and cost-effective tools that can aid in the preoperative distinction of chRCC from oncocytoma, potentially guiding treatment planning.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Urology, Health Sciences University, Hamidiye Faculty of Medicine, Istanbul Health Practice and Research Center, Istanbul, Turkey.
- Department of Urology, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul, Turkey.
- Department of Urology, University of Health Sciences Kartal Dr. Lütfi Kırdar City Hospital, Istanbul, Turkey.
- Department of Urology, University of Health Sciences Prof. Dr. Cemil Taşcıoğlu City Hospital, Istanbul, Turkey.
- Department of Urology, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul, Turkey, mustafa.kadihasanoglu@gmail.com.
Zitieren
APA
Aktaş, S., Beşiroğlu, H., Sevinç, A. H., Bozkurt, M., Ateş, H. A., & Kadıhasanoğlu, M. (2025). Preoperative Role of Systemic Immune Indices in the Differential Diagnosis between Chromophobe Renal Cell Carcinoma and Oncocytoma. Urologia Internationalis. https://doi.org/10.1159/000549555
Vancouver
Aktaş S, Beşiroğlu H, Sevinç AH, Bozkurt M, Ateş HA, Kadıhasanoğlu M. Preoperative Role of Systemic Immune Indices in the Differential Diagnosis between Chromophobe Renal Cell Carcinoma and Oncocytoma. Urologia Internationalis. 2025. doi:10.1159/000549555
BibTeX
@article{Akta2025,
author = {Aktaş, Semih and Beşiroğlu, Hüseyin and Sevinç, Ahmet Halil and Bozkurt, Muammer and Ateş, Hüseyin Aytaç and Kadıhasanoğlu, Mustafa},
title = {Preoperative Role of Systemic Immune Indices in the Differential Diagnosis between Chromophobe Renal Cell Carcinoma and Oncocytoma},
journal = {Urologia Internationalis},
year = {2025},
doi = {10.1159/000549555}
}
EUVIMED